Literature DB >> 19885864

The galanin receptor 2/3 agonist Gal2-11 protects the SN56 cells against beta-amyloid 25-35 toxicity.

S Pirondi1, A Giuliani, G Del Vecchio, L Giardino, T Hökfelt, L Calzà.   

Abstract

The neuropeptide galanin is a modulator of cholinergic function and may play a role in A beta peptide-induced degeneration of cholinergic forebrain neurons. We have studied the effect of galanin and its galanin receptor subtype 2/3 agonist Gal2-11on toxicity induced by freshly-prepared beta-amyloid(25-35) in the cholinergic cell line SN56. Both nuclear fragmentation and caspase-3 expression were analysed. beta-amyloid(25-35)-exposure induced a significant increase in caspase-3 mRNA expression after 30, 60, 90 or 150 min of beta-amyloid(25-35) exposure. These effects were abolished in the presence of Gal2-11 (10 nM). Similarly, beta-amyloid(25-35)-induced nuclear fragmentation was prevented by the galanin agonist at all time points studied. These findings indicate that the galanin 2/3 agonist Gal2-11 protects SN56 cholinergic cells from beta-amyloid(25-35)-induced cell death and that this action is mediated by an early reduction of caspase-3 expression. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19885864     DOI: 10.1002/jnr.22278

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  4 in total

1.  Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.

Authors:  Joanna L Elson; Rafael Kochaj; Richard Reynolds; Ilse S Pienaar
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

2.  Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2.

Authors:  Caroline R Elliott-Hunt; Fiona E Holmes; Dean M Hartley; Sylvia Perez; Elliott J Mufson; David Wynick
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Galanin receptors and ligands.

Authors:  Kristin E B Webling; Johan Runesson; Tamas Bartfai; Ulo Langel
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-07       Impact factor: 5.555

Review 4.  Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson's Disease.

Authors:  Nicole Elaine Chambers; Kathryn Lanza; Christopher Bishop
Journal:  Front Pharmacol       Date:  2020-01-15       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.